Charles River Laboratories International, Inc. is a leading, non-clinical global drug development partner. The company has built upon its original core competency of laboratory animal medicine and science (research model technologies) to develop a diverse portfolio of discovery and safety assessment services, both Good Laboratory Practice (GLP) and non-GLP, that supports its clients from target identification through non-clinical development. It also provides a suite of products and services to support its clients' manufacturing activities. The company's broad portfolio of products and services enables its clients to create a more efficient and flexible drug development model, which reduces their costs, enhances their productivity and effectiveness, and increases speed to market. The company operates in 155 sites and in over 20 countries worldwide. Its client base includes major global pharmaceutical companies, many biotechnology companies, agricultural and industrial chemical, life science, veterinary medicine, medical device, diagnostic and consumer product companies; contract research and contract manufacturing organizations; and other commercial entities, as well as leading hospitals, academic institutions, and government agencies around the world.

• Employees: 21,800 (as of December 30, 2023)
• Geographic Footprint: Over 20 countries worldwide
• Headquarters: Wilmington, Massachusetts
• Founded: 1947
• Number of locations/facilities: 155
• Revenue: $4.1 billion (FY2023)
• Key Subsidiaries/Brands: CRADL, Endosafe, Celsis, Accugenix

• CEO: James C. Foster
• CFO: Flavia Pease
• Chief Operating Officer: Birgit Girshick
• Chief People Officer: Victoria Creamer

James C. Foster joined the company in 1976 and has been CEO since 1992. Flavia Pease joined in 2022. Birgit Girshick joined in 1989 and became COO in 2021. Victoria Creamer joined in 2019.

• Annual Revenue: $4.1 billion (FY2023)
• Net Income: $474.6 million
• Total Assets: Not available
• Key Financial Highlights: Revenue increased by 3.9% year-over-year. Net income decreased by $11.6 million year-over-year.

The company operates through three segments:

• Research Models and Services (RMS): Production and sale of research models, including rodents and non-human primates, and related services. It also includes Insourcing Solutions, Genetically Engineered Models and Services, and Research Animal Diagnostic Services.
• Discovery and Safety Assessment (DSA): Outsourced drug discovery research, non-clinical development, and regulatory-required safety testing services.
• Manufacturing Solutions: Products and services to ensure the quality and safe production of commercial therapies, including microbial detection and identification and contract development and manufacturing solutions for cell and gene therapies.

• Research Models and Services (RMS): 19.2% of total revenue (FY2023)
• Discovery and Safety Assessment (DSA): 63.3% of total revenue (FY2023)
• Manufacturing Solutions: 17.4% of total revenue (FY2023)

The company's objective is to be the scientific partner of choice to accelerate biomedical research and therapeutic innovation. Its strategy is to deliver a comprehensive and integrated portfolio of drug discovery and non-clinical development products, services and solutions to support its clients' discovery and early-stage drug research, process development, scale up, manufacturing and product release efforts, and enable them to bring new and improved therapies to market faster and more cost effectively. The company is focused on an integrated early-stage portfolio, a comprehensive biopharmaceutical manufacturing portfolio, and deep scientific expertise. It is also committed to animal welfare and has invested in alternative methodologies to reduce animal use.

• Key strategic initiatives include expanding service capabilities into cell and gene therapy, accelerating clients' path to market, and expanding geographic reach.
• Growth drivers include the evolving biopharmaceutical R&D business model, the creation of new biotechnology companies, and the increasing complexity of new treatments.
• Investment priorities include strategic acquisitions and partnerships to enhance scientific capabilities and expand the global scale.

The company operates in the non-clinical drug development industry, which is highly competitive. The company's competitors include other non-clinical drug development partners, blood product and therapeutic services companies, other CDMOs, as well as internal discovery and development departments within its larger clients. The company also competes with universities and teaching hospitals for outsourced services. The company competes on the basis of its therapeutic and scientific expertise, quality, reputation, flexibility, responsiveness, pricing, innovation and global capabilities.

• Market Position: A leading, non-clinical global drug development partner.
• Key Competitors: Not explicitly listed in the 10K.
• Industry Trends: The pharmaceutical and biotechnology industries are increasingly outsourcing their drug discovery, development and manufacturing processes.

• Business and Operational Risks: Financial risk for contracts that may be terminated or reduced in scope, underpriced, subject to cost overruns or delays; unauthorized access into information systems; and risks relating to operating internationally.
• Industry Risk Factors: Dependence on limited sources of supply, such as non-human primates; demand volatility; changes in government regulation; and competition.
• Legal and Regulatory Risk Factors: Failure to comply with applicable regulations and related guidance; failure to comply with data privacy and security laws; and failure to comply with environmental, health and safety laws.